COMPANY PROFILE

Juventas

Juventas is a biotechnology company developing immunological therapies that activate natural processes to repair the body

Hexi District, ChinaFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Juventas

Juventas is a next-generation biopharmaceutical company that leverages cutting-edge cellular and genetic technologies to develop advanced therapies for hematologic malignancies, solid tumors, and autoimmune diseases. The company operates in the biopharmaceutical market, focusing on innovative cell therapies. Its core clients include patients suffering from relapsed and refractory acute lymphoblastic leukemia, aggressive B cell non-Hodgkin lymphoma, and pediatric B cell acute lymphoblastic leukemia.

Juventas' business model revolves around rigorous clinical development and a scalable pipeline of product candidates. The company has obtained three Investigational New Drug (IND) approvals from the National Medical Products Administration (NMPA) in China. These approvals enable Juventas to conduct clinical trials and bring its therapies closer to market.

Revenue is generated through the development and commercialization of its immune cell therapy products, which are produced under stringent manufacturing and quality control systems. Juventas also engages in strategic collaborations, such as its partnership with Thermo Fisher Scientific, to advance technological innovation in universal cell therapy.

The company's portfolio includes over 10 product candidates, featuring innovative single and multiple target products as well as universal cell therapy products. This expansive and competitive pipeline positions Juventas as a leader in the biopharmaceutical industry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Hexi District, China
Employees: 31
Open positions: 2
Dealroom signal: 39.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Jul 2021	$63M	$345M	Tianjin Venture Capital · Delian Capital · Dalton Venture · Redhill Capital	—
SERIES BOther financing	Nov 2020	$69M	$276M	Tianjin Venture Capital · Dalton Venture · CMG-SDIC Capital · Panacea Venture	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Juventas website traffic

Latest recorded traffic for Juventas is 3.3K monthly website visits, up 65% over the last three months. Juventas's team declined 3.1% over the past year.

Latest monthly visits3.3K 3-month web change+65% 1-year team growth-3.1%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

-QCTianjin, Tianjin, China · Other · Jul 10, 2026 OTCWuhan, Hubei, China · Other · Jun 11, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SPSplisenseDeveloping transformative RNA-based treatments for unmet needs relating to CF and other genetic pulmonary illnesses	Jerusalem, Israel	Operational	16	$42M	$114M
FBForge BiologicsA gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality	Columbus, United States	Acquired
OBOri BiotechAutomates and standardizes cell and gene therapy manufacturing to enable scalable development from R&D to commercial production	London, United Kingdom	Operational
C4C4UC4U Corporation is a developer of a genome editing technology	Suita-Shi, Japan	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational
THThinkCyteAI-based, label-free cell analysis and sorting instruments	Tokyo, Japan	Operational
CECellSpringThe Next Level in 3D Cell Culture	Zurich, Switzerland	Operational